Latest ORIC reports update at 2024-05-06: 2024-Q1 ∙ 2023-Q4 ∙ 2023-Q1

ORIC Pharmaceuticals ORIC

$ 8.63 0.94%

ORIC Pharmaceuticals Balance Sheet 2011-2024 | ORIC

Annual Balance Sheet ORIC Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-13.2 M	-54.7 M	-214 M	-78.4 M	-89.2 M	-42.6 M	-	-	-	-	-	-	-
Long Term Debt	7.46 M	9.44 M	10.5 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	2.75 M	2.66 M	1.93 M	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	765 K	109 M	-	-	-	-	-	-	-
Total Current Liabilities	20.5 M	15.4 M	15.2 M	9 M	-	-	-	-	-	-	-	-	-
Total Liabilities	27.9 M	24.8 M	25.7 M	9.22 M	6.12 M	111 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-435 M	-334 M	-245 M	-	-92.7 M	-65.8 M	-	-	-	-	-	-	-
Total Assets	252 M	247 M	299 M	299 M	94.1 M	46.7 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	23.4 M	66.8 M	226 M	78.4 M	89.2 M	42.6 M	-	-	-	-	-	-	-
Book Value	224 M	222 M	273 M	290 M	88 M	-64.4 M	-	-	-	-	-	-	-
Total Shareholders Equity	224 M	222 M	273 M	290 M	-90.1 M	-64.4 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet ORIC Pharmaceuticals

	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	-	-	-	10.5 M	10.7 M	-	600 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	22.1 M	27.9 M	26.9 M	23 M	23.8 M	24.8 M	23.2 M	22.8 M	22 M	25.7 M	22.6 M	9.9 M	7.88 M	9.22 M	9.22 M	9.22 M	9.22 M	6.12 M	6.12 M	6.12 M	6.12 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-460 M	-435 M	-407 M	-381 M	-358 M	-334 M	-313 M	-289 M	-268 M	-245 M	-222 M	-204 M	-183 M	-166 M	-166 M	-166 M	-166 M	-92.7 M	-92.7 M	-92.7 M	-92.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	351 M	252 M	274 M	292 M	227 M	247 M	238 M	260 M	275 M	299 M	314 M	268 M	284 M	299 M	299 M	299 M	299 M	94.1 M	94.1 M	94.1 M	94.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	56.4 M	23.4 M	26.2 M	104 M	59 M	66.8 M	29.1 M	49.1 M	113 M	226 M	241 M	170 M	104 M	78.4 M	78.4 M	78.4 M	78.4 M	89.2 M	89.2 M	89.2 M	89.2 M	42.6 M	-	-	-	25.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	329 M	224 M	247 M	269 M	203 M	222 M	215 M	237 M	253 M	273 M	292 M	258 M	276 M	290 M	290 M	290 M	290 M	88 M	88 M	88 M	88 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	329 M	224 M	247 M	269 M	203 M	222 M	215 M	237 M	253 M	273 M	292 M	258 M	276 M	290 M	290 M	290 M	290 M	-90.1 M	-90.1 M	-90.1 M	-90.1 M	-64.4 M	-	-	-	-43.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency